{
  "paper_id": "PMC6627238",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627238/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1. The breast: structure, risk factors and stages of cancer development.",
      "caption": "(A) Schematic of the human breast highlighting terminal ductal lobular units (TDLUs), the site of origin in a number of breast cancers. (B) Some of the major risk factors underlying high‐risk status for breast cancer. (C) Schematic of a ductal cross‐section, depicting the progression of breast cancer from normal bi‐layered epithelium to hyperplasia, to hyperplasia with atypia, to ductal carcinoma in situ, and finally to invasive disease.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/e40939d02615/EMBJ-38-e100852-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/e40939d02615/EMBJ-38-e100852-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/e40939d02615/EMBJ-38-e100852-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/e40939d02615/EMBJ-38-e100852-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "embj2018100852-fig-0001",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/e40939d02615/EMBJ-38-e100852-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC6627238/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/e40939d02615/EMBJ-38-e100852-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2. Progesterone‐driven cellular and molecular changes in the mammary gland.",
      "caption": "(A) The murine estrous cycle is shown with mammary whole mounts depicting the gross morphological changes elicited by fluctuations in the ovarian hormones, estrogen, and progesterone. The corresponding expansion in mammary stem and progenitors is also highlighted. Schematic illustrates the strategy of utilizing factors that limit stem/progenitor expansion as chemopreventive agents in breast cancer. Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8062a3e7ff7e/EMBJ-38-e100852-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8062a3e7ff7e/EMBJ-38-e100852-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8062a3e7ff7e/EMBJ-38-e100852-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8062a3e7ff7e/EMBJ-38-e100852-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "embj2018100852-fig-0002",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8062a3e7ff7e/EMBJ-38-e100852-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC6627238/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8062a3e7ff7e/EMBJ-38-e100852-g002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3. Lineage‐specific molecular programs and epigenetic regulators.",
      "caption": "(A) Schematic illustrating the main GO terms biological processes (≥ 3‐fold upregulated, FDR ≤ 0.01) enriched in the three distinct mammary cell subpopulations in response to progesterone, based on proteomic analysis from Casey et al. (B) Visualization of the indicated epigenetic proteins or histone marks (green) in situ. Lineage specificity is observed for select proteins (EZH2, DNMT1, and SETD7). Cytokeratin 5 (red) marks the basal compartment. (C) Comparative abundance of epigenetic regulatory proteins detected in luminal vs. basal compartment.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8a1818e2e4e7/EMBJ-38-e100852-g003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8a1818e2e4e7/EMBJ-38-e100852-g003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8a1818e2e4e7/EMBJ-38-e100852-g003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8a1818e2e4e7/EMBJ-38-e100852-g003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "embj2018100852-fig-0003",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8a1818e2e4e7/EMBJ-38-e100852-g003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC6627238/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/8a1818e2e4e7/EMBJ-38-e100852-g003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4. A path to OMICS‐guided chemoprevention.",
      "caption": "A workflow modeling a discovery‐to‐intervention pipeline for OMICs‐guided chemoprevention. FACS‐purified mammary cell populations are the input for integrative molecular profiling, target validation, rationalized drug identification, and evaluation in a series of biological, pre‐clinical assays.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/22bfa807c62c/EMBJ-38-e100852-g004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/22bfa807c62c/EMBJ-38-e100852-g004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/22bfa807c62c/EMBJ-38-e100852-g004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/22bfa807c62c/EMBJ-38-e100852-g004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "embj2018100852-fig-0004",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/22bfa807c62c/EMBJ-38-e100852-g004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC6627238/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4623/6627238/22bfa807c62c/EMBJ-38-e100852-g004.jpg"
    }
  },
  "claims": [
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This overarching workflow is depicted in Fig 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 4,
    "claims_count": 64,
    "images_downloaded": 4,
    "tables_filtered": 8
  }
}